The Cardio Vascular Clinical Trialists Forum (CVCT) serves as a unique think tank, focusing on the latest critical trials in the fields of CardioVascular, CardioRenal, and Cardiometabolic health. It provides a platform for authoritative stakeholders to spend hours delving into individual trials, examining them both individually and in context. The forum aims to foster collaboration, brainstorming, and knowledge-sharing among key clinical trial players.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
